|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
June 2009FeaturesCover Story Genetic Testing: Counselors Desperately NeededGenetic tests are proliferating, and payers, PBMs, and professional societies are developing in-house expertise to fill the counseling gap. All agree that more education programs and clinical decision tools are needed. But hard questions about data validity have to be answered first if personalized medicine is to become a reality. BFAC Perspectives Turning A Blind Eye To ValueEmployers want value in benefit design. Why don’t they get it? Advocating Awareness: The Push for Prostate Cancer ScreeningNew tests and techniques aim to alter the male mindset and raise public consciousness about this disease. What GINA Wants, Will Gina Get?Legislation protecting the privacy of genetic testing results took effect late last month. And for all the good it could do — such as prompting interventions that could reduce downstream costs of advanced disease — there is still uncertainty about how far the law’s protections extend. Q&A An Interview with Dr. Donald Berwick: Rethinking Comparative Effectiveness ResearchOpponents to the new CER legislation are raising red flags, warning about a one-size-fits-all treatment approach and the rationing of healthcare. But Dr. Donald Berwick, president and CEO of the Institute for Healthcare Improvement, says to look at which interventions are effective — but not what they cost — is irrational and simply bad policy.
Patient Medication Adherence: The Forgotten Aspect of BiologicsThe full benefit of biologic therapies isn’t reached and quality of life is compromised if patients don’t adhere to their medication regimen. Are adherence interventions in order? DepartmentsOpeners The Official Journal of BFAC
Michael D. Dalzell Editorial Congress Must Confront the Biologic Frontier
David B. Nash, MD, MBA Personalized Medicine First-in-Class Product Seeks to Promote Better Prescribing Habits
Bob Carlson, MHA Drug Track Research, Conferences, and FDA ActionsSpecialty Pharmacy Managing Second-line Biologics: Worth the Effort?Biologics and Benefits Having Mined Gold in Pharmacy Deal, Caterpillar Sets Sights on Gold-Standard TherapiesNew department focuses on employers that view benefit designs as a business strategy. Trends Search for Vaccines: Opportunity in Tragedy |
|||||